Tag
Articles about AI drug discovery from podcasts, articles and papers, with links to the original sources.
On Training Data, Box CEO Aaron Levie was asked where enterprise AI memory is heading — retrieval, or models whose weights absorb a company's knowledge. His answer started with a lawyer who can see five matters and whose access changes daily, and ended with a wish for a rubric deciding what gets baked in and what stays a lookup.
On Moonshots, Peter Diamandis and his panel seized on an exploratory analysis of rentosertib, a drug whose target and molecule were chosen by Insilico Medicine's AI. In 42 patients with a fatal lung disease, blood-protein "aging clocks" shifted a few years younger by week four. The clocks tied to mortality risk did not move significantly, the signal plateaued by week 12, and the study's authors call the result a biomarker finding, not evidence of a longer life.
On The Diary of a CEO, investor David Friedberg described a cell as a city of 10 billion workers and argued that AI lets researchers screen a million protein ideas on computers before touching a lab bench. His worked example is partial epigenetic reprogramming — and a June 2026 announcement shows that work has reached a first safety trial in human eyes, not restored sight.
GenBio AI's AIDO Cell simulates a human cell that holds its state across a sequence of interventions, and the Moonshots panel watched a demo and began sketching the end of medicine. The article explains what the simulator does today — prioritizing experiments in two prototype cell lines, with laboratory validation of novel predictions still underway — and separates that from the panel's proposals: an AlphaGo-style search from diseased to healthy cells, open public biology data, and frontier labs paying for all of it.
Merck and Moderna said on August 19 that intismeran autogene, an mRNA therapy manufactured separately for every patient, met its main endpoints alongside Keytruda in a 1,137-patient melanoma trial. On the Moonshots podcast, the panel walked through the sequencing-and-machine-learning workflow behind it and argued about whether drug regulation can cope with a treatment that is different for each person.
NVIDIA reported $96.2 billion in quarterly revenue and guided to $108 billion for the current quarter. On Moonshots with Peter Diamandis, the panel split over what the number proves: Dave Blundin sees a company nobody can avoid, Alex wants to know how much of the demand NVIDIA itself financed, and Salim Ismail would prefer slower growth that markets have time to correct.
Bernie Sanders invoked the AI labs’ own safety commitments in demanding a development pause. On Moonshots, Emad Mostaque and the panel argued instead for controls on biological synthesis and faster detection of threats—but a proposal to monitor every AI prompt raised a different question: how much privacy would those defenses cost?